SB-509 clinical trials
Also written SB-509.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses SB-509 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SB-509
- 5
Studies by the year they started
5 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses SB-509 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedPhase 2Sangamo TherapeuticsNCT01079325Written as SB-509How we know
- Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedPhase 2Sangamo TherapeuticsNCT00476931Written as SB-509How we know
- Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2Sangamo TherapeuticsNCT00748501Written as SB-509How we know
- Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedPhase 2Sangamo TherapeuticsNCT00406458Written as SB-509How we know
- Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509CompletedPhase 2Sangamo TherapeuticsNCT00665145Written as SB-509How we know